648 related articles for article (PubMed ID: 29965858)
1. Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin.
Jain V; Mohebtash M; Rodrigo ME; Ruiz G; Atkins MB; Barac A
J Immunother; 2018 Sep; 41(7):332-335. PubMed ID: 29965858
[TBL] [Abstract][Full Text] [Related]
2. Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy.
Tajmir-Riahi A; Bergmann T; Schmid M; Agaimy A; Schuler G; Heinzerling L
J Immunother; 2018 Jan; 41(1):35-38. PubMed ID: 29077601
[TBL] [Abstract][Full Text] [Related]
3. Two Cases of Sinusitis Induced by Immune Checkpoint Inhibition.
Dein E; Sharfman W; Kim J; Gellad F; Shah AA; Bingham CO; Cappelli LC
J Immunother; 2017 Oct; 40(8):312-314. PubMed ID: 28614096
[TBL] [Abstract][Full Text] [Related]
4. What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events.
Miranda Poma J; Ostios Garcia L; Villamayor Sanchez J; D'errico G
Allergol Immunopathol (Madr); 2019; 47(3):303-308. PubMed ID: 29983240
[TBL] [Abstract][Full Text] [Related]
5. [Progress in immune checkpoint inhibitor therapies].
Akatsuka Y
Rinsho Ketsueki; 2019; 60(9):1341-1350. PubMed ID: 31597862
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia.
Smithy JW; Pianko MJ; Maher C; Postow MA; Shoushtari AN; Momtaz P; Chapman PB; Wolchok JD; Park JH; Callahan MK
J Immunother; 2021 Jan; 44(1):9-15. PubMed ID: 33290361
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expressing granulomatous reaction as an on-target mechanism of steroid-refractory immune hepatotoxicity.
Black JR; Goldin RD; Foxton M; Marafioti T; Akarca AU; Pria AD; Brock C; Bower M; Pinato DJ
Immunotherapy; 2019 May; 11(7):585-590. PubMed ID: 30943859
[TBL] [Abstract][Full Text] [Related]
8. Development of Bell's Palsy After Treatment With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report.
Zecchini JM; Kim S; Yum K; Friedlander P
J Immunother; 2018 Jan; 41(1):39-41. PubMed ID: 28926356
[TBL] [Abstract][Full Text] [Related]
9. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
Scott ES; Long GV; Guminski A; Clifton-Bligh RJ; Menzies AM; Tsang VH
Eur J Endocrinol; 2018 Feb; 178(2):173-180. PubMed ID: 29187509
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic virotherapy, alone or in combination with immune checkpoint inhibitors, for advanced melanoma: A systematic review and meta-analysis.
Zou P; Tang R; Luo M
Int Immunopharmacol; 2020 Jan; 78():106050. PubMed ID: 31812724
[TBL] [Abstract][Full Text] [Related]
11. Hypohidrosis as an immune-related adverse event of checkpoint inhibitor therapy.
Kersh AE; Schuchter LM; Elenitsas R; Chu EY
Immunotherapy; 2020 Sep; 12(13):951-956. PubMed ID: 32772616
[No Abstract] [Full Text] [Related]
12. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy.
Balanescu DV; Donisan T; Palaskas N; Lopez-Mattei J; Kim PY; Buja LM; McNamara DM; Kobashigawa JA; Durand JB; Iliescu CA
Cardiovasc Pathol; 2020; 47():107211. PubMed ID: 32268262
[TBL] [Abstract][Full Text] [Related]
13. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.
Reddy SB; Possick JD; Kluger HM; Galan A; Han D
J Immunother; 2017 Oct; 40(8):307-311. PubMed ID: 28737620
[TBL] [Abstract][Full Text] [Related]
14. The forgotten role of adjuvant immune checkpoint inhibitors in preventing melanoma brain metastasis.
El Rassy E; Farhat F; Kattan J
Immunotherapy; 2018 Nov; 10(15):1289-1291. PubMed ID: 30474477
[No Abstract] [Full Text] [Related]
15. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
[TBL] [Abstract][Full Text] [Related]
16. Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls.
Darnell EP; Mooradian MJ; Baruch EN; Yilmaz M; Reynolds KL
Curr Oncol Rep; 2020 Mar; 22(4):39. PubMed ID: 32200442
[TBL] [Abstract][Full Text] [Related]
17. Three cases of nivolumab therapy-failed advanced melanoma successfully controlled by ipilimumab with intensity-modulated radiotherapy.
Amagai R; Fujimura T; Kambayashi Y; Sato Y; Tanita K; Hashimoto A; Aiba S
J Dermatol; 2019 May; 46(5):449-452. PubMed ID: 30908705
[TBL] [Abstract][Full Text] [Related]
18. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
[TBL] [Abstract][Full Text] [Related]
19. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.
Saibil SD; Bonilla L; Majeed H; Sotov V; Hogg D; Chappell MA; Cybulsky M; Butler MO
Curr Oncol; 2019 Jun; 26(3):e418-e421. PubMed ID: 31285688
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune Cardiotoxicity of Cancer Immunotherapy.
Cheng F; Loscalzo J
Trends Immunol; 2017 Feb; 38(2):77-78. PubMed ID: 27919707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]